Olpresan (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olpresan, is an angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension and may be used in adults who require blood pressure control. GNH USA supplies Olpresan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olpresan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olpresan is an angiotensin‑II receptor blocker indicated for conditions affecting the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: helps slow progression of kidney damage associated with type 2 diabetes.

Adverse reactions to olmesartan may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhoea - Back pain

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Liver enzyme elevation - Severe hypotension - Bullous pemphigoid skin reaction

Olpresan should be used with caution in specific clinical situations.

- Pregnancy: contraindicated in the second and third trimesters due to risk of fetal toxicity. - Renal impairment: dose adjustment may be required; monitor kidney function. - Hyperkalemia risk: monitor serum potassium, especially when combined with potassium‑sparing diuretics. - Concomitant NSAID use: may reduce antihypertensive effect and increase renal risk. - Elderly patients: start with lower dose and titrate slowly. - Store at below 25°C: keep in the original packaging ​​​  ");

The pharmacological interaction ");

"""""  "" """""""""""""""""""""""""""""""""""""""""""""""""""""""""""